AI CuratorAI-generated

Research summary · 7 d ago

AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

CAR-T Cell Therapy in Progressive MS Patients

In a study involving two patients with progressive MS, treatment with 0.33x10^8 anti-CD19 CAR-T cells (mivocabtagene autoleucel) was found to be safe. The therapy penetrated the cerebrospinal fluid (CSF) effectively and led to a resolution of oligoclonal bands along with a normalization of the IgG index. EDSS scores appeared stabilized over a 48-week follow-up.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42818477)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This study highlights a potential new approach to treating progressive MS, focusing on the safety and effects of CAR-T therapy on immune responses and disease stabilization.

What this does not prove

Findings are based on only two subjects, limiting generalizability. Additionally, the lack of randomized controlled trial design restricts conclusions about efficacy, and the study has not been peer-reviewed.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 2 · basis not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-11
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceImmune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis. ↗DOI: 10.64898/2026.09.11.26361992

Supporting passages (6)

sample size2

publication date2026-09-11

intervention0.33×10^8 autologous anti-CD19 CAR-T cells (mivocabtagene autoleucel, miv-cel)

follow upWeek 48

findingsIn the 2 subjects with progressive MS reported here, low dose anti-CD19 CAR-T cell therapy (miv-cel) was safe, penetrated the CSF effectively, reduced intrathecal humoral activity, modulated peripheral immune tone, and appeared to stabilize EDSS scores.

limitationsTitle: Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.